Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5833661 | 0.85 | POLB (0.40) | POLBGPR119ALDH1A1KDM4ETP53 | |
| SCHEMBL30594001 | 0.85 | POLB (0.40) | POLBGPR119ALDH1A1KDM4ETP53 | |
| SCHEMBL27838787 | 0.83 | POLB (0.38) | POLBGPR119ALDH1A1KDM4ETP53 | |
| SCHEMBL29659142 | 0.77 | POLB (0.44) | POLBGPR119ALDH1A1SMN1; SMN2PAX8 | |
| SCHEMBL25763092 | 0.77 | PAX8 (0.35) | POLBGPR119ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL6601505 | 0.77 | POLB (0.44) | POLBGPR119ALDH1A1SMN1; SMN2PAX8 | |
| SCHEMBL31491952 | 0.76 | PAX8 (0.34) | ALDH1A1PAX8SSTR4USP30 | |
| SCHEMBL9072452 | 0.76 | PAX8 (0.34) | ALDH1A1PAX8AAK1USP30 | |
| SCHEMBL972752 | 0.76 | PAX8 (0.34) | ALDH1A1PAX8SSTR4USP30 | |
| SCHEMBL26947077 | 0.76 | PAX8 (0.34) | ALDH1A1PAX8AAK1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2683394-B1 | ACTIVE AGENT PRODRUGS WITH HETEROCYCLIC LINKERS | SIGNATURE THERAPEUTICS INC (US) | 2021-01-06 | — | — | EP | disclosed |
| US-20160002291-A1 | Active Agent Prodrugs with Heterocyclic Linkers | SIGNATURE THERAPEUTICS INC (US) | 2016-01-07 | — | — | US | disclosed |
| US-9139612-B2 | Active agent prodrugs with heterocyclic linkers | SIGNATURE THERAPEUTICS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9095627-B2 | Opioid prodrugs with heterocyclic linkers | SIGNATURE THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140206597-A1 | Opioid Prodrugs with Heterocyclic Linkers | 3I, LP | 2014-07-24 | — | — | US | disclosed |
| US-20140121152-A1 | Active Agent Prodrugs with Heterocyclic Linkers | SIGNATURE THERAPEUTICS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| EP-2683394-A2 | ACTIVE AGENT PRODRUGS WITH HETEROCYCLIC LINKERS | Signature Therapeutics, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| US-20120295834-A1 | Opioid Prodrugs with Heterocyclic Linkers | 3I, LP | 2012-11-22 | — | — | US | disclosed |
| WO-2012122420-A2 | OPIOID PRODRUGS WITH HETEROCYCLIC LINKERS | PHARMACOFORE, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012122422-A2 | ACTIVE AGENT PRODRUGS WITH HETEROCYCLIC LINKERS | SIGNATURE THERAPEUTICS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012116629-A1 | MANGIFERIN AGLYCON DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | 上海长征医院 (CN) | 2012-09-07 | — | — | WO | disclosed |
| US-7884109-B2 | immunosuppressants such as 2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4R)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)-7H-purin-8(9H)-one, used for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection | WYETH LLC (US) | 2011-02-08 | — | — | US | disclosed |
| EP-2099800-A1 | 7-SUBSTITUTED PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | Pharmacopeia, LLC (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080287468-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| WO-2008060301-A1 | 7-SUBSTITUTED PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA , LLC (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080119496-A1 | 7-Substituted Purine Derivatives for Immunosuppression | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| EP-1874772-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | WYETH LLC | 2007-01-25 | — | — | US | disclosed |
| WO-2006108103-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119496-A1 | 7-Substituted Purine Derivatives for Immunosuppression | P2RX7, P2RX5, P2RY1 | POLB 3181/4885GPR119 638/4885ALDH1A1 298/4885 |
| US-20140121152-A1 | Active Agent Prodrugs with Heterocyclic Linkers | PEPD, SI, PREP | POLB 2534/4885GPR119 760/4885ALDH1A1 1956/4885 |
| US-20120295834-A1 | Opioid Prodrugs with Heterocyclic Linkers | OPRK1, OPRM1, PREP | POLB 1733/4885GPR119 1189/4885ALDH1A1 1622/4885 |
| US-20140206597-A1 | Opioid Prodrugs with Heterocyclic Linkers | OPRK1, OPRM1, PREP | POLB 1733/4885GPR119 1189/4885ALDH1A1 1622/4885 |
| US-20160002291-A1 | Active Agent Prodrugs with Heterocyclic Linkers | PEPD, SI, PREP | POLB 2534/4885GPR119 760/4885ALDH1A1 1956/4885 |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | TPMT, P2RY4, P2RY1 | POLB 3467/4885GPR119 189/4885ALDH1A1 514/4885 |
| US-20080287468-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | TPMT, P2RY4, P2RY1 | POLB 3467/4885GPR119 189/4885ALDH1A1 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.